A Positive Selection for Nucleoside Kinases in E. coli.
Engineering heterologous nucleoside kinases inside E. coli is a difficult process due to the integral role nucleosides play in cell division and transcription. Nucleoside analogs are used in many kinase screens that depend on cellular metabolization of the analogs. However, metabolic activation of these analogs can be toxic through disruptions of DNA replication and transcription because of the analogs' structural similarities to native nucleosides. Furthermore, the activity of engineered kinases can be masked by endogenous kinases in the cytoplasm, which leads to more difficulties in assessing target activity. A positive selection method that can discern a heterologous kinases' enzymatic activity without significantly influencing the cell's normal metabolic systems would be beneficial. We have developed a means to select for a nucleoside kinase's activity by transporting the kinase to the periplasmic space of an E. coli strain that has its PhoA alkaline phosphatase knocked out. Our proof-of-principle studies demonstrate that the herpes simplex virus thymidine kinase (HSV-TK) can be transported to the periplasmic space in functional form by attaching a tat-signal sequence to the N-terminus of the protein. HSV-TK phosphorylates the toxic nucleoside analog 3'-azido-3'-deoxythymidine (AZT), and this charged, monophosphate form of AZT cannot cross the inner membrane. The translocation of HSV-TK provides significant resistance to AZT when compared to bacteria lacking a periplasmic HSV-TK. However, resistance decreased dramatically above 40 μg/ml AZT. We propose that this threshold can be used to select for higher activity variants of HSV-TK and other nucleoside kinases in a manner that overcomes the efficiency and localization issues of previous selection schemes. Furthermore, our selection strategy should be a general strategy to select or evaluate nucleoside kinases that phosphorylate nucleosides such as prodrugs that would otherwise be toxic to E. coli.
Chemical Biology Interface Graduate Program, Johns Hopkins University, 3400 N. Charles St., Baltimore, MD 21218, United States of America.
Nirav Y
NY
Shelat
Department of Chemical & Biomolecular Engineering, Johns Hopkins University, 3400 N. Charles St., Baltimore, MD 21218, United States of America.
Sidhartha
S
Parhi
Department of Chemical & Biomolecular Engineering, Johns Hopkins University, 3400 N. Charles St., Baltimore, MD 21218, United States of America.
Marc
M
Ostermeier
Nat Rev Drug Discov. 2013 Jun;12(6):447-64
23722347
Annu Rev Microbiol. 2006;60:373-95
16756481
J Bacteriol. 1993 Sep;175(18):6049-51
8376351
Org Biomol Chem. 2005 Feb 7;3(3):462-70
15678184
Nucleic Acids Res. 2011 Feb;39(3):e12
21062820
J Nucl Med. 2010 Sep;51(9):1395-403
20810757
Cancer Lett. 2008 Nov 8;270(2):191-201
18502571
Proc Natl Acad Sci U S A. 1993 May 1;90(9):4012-6
8387207
J Biol Chem. 1967 Sep 10;242(17):3905-11
5341266
Proc Natl Acad Sci U S A. 1996 Apr 16;93(8):3525-9
8622970
Front Microbiol. 2015 Apr 30;6:402
25983732
Biochemistry. 2010 Aug 10;49(31):6784-90
20614893
Anticancer Drug Des. 1999 Dec;14(6):517-38
10834273
Cancer Res. 1997 Oct 15;57(20):4537-44
9377566
Mol Biochem Parasitol. 2001 Aug;116(1):85-8
11463470
Open Biochem J. 2008;2:60-6
18949076
Appl Environ Microbiol. 2005 Aug;71(8):4339-44
16085822
PLoS One. 2014 Nov 26;9(11):e114032
25426963
J Biol Chem. 1992 Apr 5;267(10):6584-9
1313013
J Bacteriol. 2007 Mar;189(6):2435-42
17209034
J Biol Chem. 1965 Sep;240(9):3685-92
4284300
Biochim Biophys Acta. 2009 May;1794(5):808-16
19100346
Oncogene. 2008 Oct 27;27(50):6522-37
18955977
Annu Rev Microbiol. 1998;52:591-625
9891809
J Bacteriol. 1983 Jan;153(1):241-52
6294049
Methods Mol Biol. 2014;1116:103-17
24395360
Biochemistry. 1993 Nov 2;32(43):11618-26
8218229
N Biotechnol. 2008 Jun;25(1):49-54
18504019
Antiviral Res. 2010 Apr;86(1):101-20
20417378
Antivir Chem Chemother. 2005;16(3):155-68
16004079
Gene Ther. 2006 Sep;13(17 ):1309-12
16810197
Nat Rev Cancer. 2003 May;3(5):330-8
12724731